Clinical Cell Culture - 500 Beiträge pro Seite

[Geldhahn]

Nach einem Anstieg um 17,9% ist die Aktie wegen einer Verlautbarung morgen ausgesetzt worden.

CLINICAL CELL CULTURE LIMITED 2003-06-16 ASX-SIGNAL-G

HOMEX - Perth

+++++++++++++++++++++++++
The securities of Clinical Cell Culture Limited (the "Company") will
be placed in pre-open at the request of the Company, pending the
release of an announcement by the Company. Unless ASX decides
otherwise, the securities will remain in pre-open until the earlier
of the commencement of normal trading on Wednesday, 18 June 2003 or
when the announcement is released to the market.

Security Code: CCE

B O`Hara
MANAGER COMPANIES

REQUEST FOR TRADING HALT

We hereby request a trading halt of the company`s listed securities
pending a further announcement tomorrow.

G Chiappini
FINANCE MANAGER


Grüsse

[jkaktien]

Der Anstieg ist ja erstmal vielversprechend.
Gibt es irgendwelche Infos, Hinweise oder Spekulationen zur angekündigten Verlautbarung?

[Geldhahn]

Leider nicht.

Grüsse

[IIBI]

Hallo Leute,

ich hab auch noch paar von den Dingern, was
soll man davon halten, ich hoffe da tut sich endlich
mal was!!

Gruß

[jkaktien]

Da bist Du mit Deiner Hoffnung nicht allein.

Leider gibt es auch unter dieser Adresse (http://www.clinicalcellculture.com/one/cp_06.asp?type=AS) noch nichts Neues.

Grüße

[Geldhahn]

Nachfolgend die Meldung, daß sich die Firma BTC mit 19,99% an CCE beteiligen will, Preis heute um 5,88% gestiegen bei 1,9 Mio Aktien:

BIOTECH CAPITAL LIMITED 2003-06-18 ASX-SIGNAL-G

HOMEX - Sydney

+++++++++++++++++++++++++
Biotech Capital Ltd to take 19.99% stake in listed tissue engineering
company Clinical Cell Culture Ltd (ASX Code: CCE)

The Directors of BioTech Capital Ltd (BTC) are pleased to announce
that BTC has entered into a Heads of Agreement to acquire a 19.99%
stake in ASX-listed tissue engineering company Clinical Cell Culture
Ltd ("C3") for a consideration of up to $2.85 million in cash. This
represents an issue price of 10.5 cents per C3 share.

BTC will also be issued with options, which upon exercise will see
its total investment in C3 rise to approximately $4 million.

Upon completion of the total funding round of $5 million, C3s cash
reserves will be approximately $8 million.

The investment is subject to C3 shareholder approval, which is
expected in July whereupon BTC will also take up a Board seat.

C3 is best known for its "spray on skin" technology, which received
widespread coverage during the treatment of many of the burns victims
from the Bali bombings. The company has a portfolio of several other
exciting products and projects in development.

BTC considers the investment to provide excellent exposure to the
exciting tissue engineering/regenerative medicine sector.
Furthermore, BTC is backing a clinically proven technology already
generating revenues which has been used in over 1,600 procedures to
date. The funds raised will be used in advancing key projects but
more importantly in seeking to open up offshore markets initially
Europe where planning is already well advanced.

This investment represents BTCs seventh investment and is the first
in a listed company. Harry Karelis, Managing Director of BTC, stated
" We have been very patient in scouring both the private and public
markets for the right opportunity to add to our portfolio and believe
that C3 represents an exceptional opportunity to generate wealth for
both C3 and BTC shareholders. The continued depressed funding
environment has opened up several opportunities in the sector and we
continue to actively assess potential new investments."

"In addition to C3, we are in the documentation stage for closing
what will be BTCs eighth investment and hope to be in a position to
announce this in the short term. Our cash levels remain very strong
placing BTC in a very good position to exploit the opportunities
available." Additional information can be found at
www.biotechcapital.com.au and www.clinicalcellculture.com.

ASX announcement by C3 follows

Contact Information
BioTech Capital Ltd
Harry Karelis
Director
Ph: [phone] / 0413 056 328
E-mail: [e-mail]
Web: www.biotechcapital.com.au


ATTACHMENT 1: RELEASE BY C3 TO AUSTRALIAN STOCK EXCHANGE
17th June 2003, PERTH, AUSTRALIA:

Clinical Cell Culture Ltd (C3, ASX:CCE) today announced that the
Company has entered into a conditional (see attached appendix for
summary of conditions) Heads of Agreement with BioTech Capital
Limited ("BTC") to subscribe for 19.99% of the issued share capital
of C3. This represents an investment of approximately $2.85 million
and will be part of a total funding round of $5 million, with the
balance being placed to clients of Emerging Growth Capital and
Poynton and Partners.

The issue price for the funding round will be 10.5 cents per C3 share
(subject to conditions see appendix) with participating investors
also receiving a 31 December 2004, $0.29 call option on approximately
a 1:7 basis. The issue price of 10.5 cents represents an 11% discount
to the volume weighted average share price over the 20 trading days
up to and including 13 June 2003. Upon completion of the funding
round, C3`s cash reserves will be in excess of $8 million.

The proposed investment by BTC is subject to shareholder approval,
which is expected at the end of July. Subject to the investment
proceeding, the Managing Director of BTC, Mr Harry Karelis will
become a member of the C3 Board.

Mr Karelis stated that BTC was attracted by C3s technology and its
focus on the commercial roll-out of its tissue engineering products.
Mr Karelis is also looking forward to joining the Board of Directors
and assisting the Company achieve its commercial objectives.

Dalton Gooding, the Chairman of C3 said that he was "very pleased to
have third party validation of our technology and the markets that we
are targeting". The Company is confident that the shareholders will
approve the placement, including the investment by BTC, and will
welcome the expertise that Mr Karelis will bring to the Board. The
Company is also confident that the additional placement will be
successfully completed.

C3s Chief Executive Office, Mr Troels Jordansen, said that he
believed the funds raised from BTC and other investors will enable
the Company to initially penetrate the European market, where he
expects it will become a significant player in the medium term.




For further information please contact:
Troels Jordansen
Clinical Cell Culture
Ph: [phone]
[e-mail]



APPENDIX

A. The proposed investment by BTC is subject to:

a. execution by BTC and C3 of a formal share subscription agreement;

b. BTC completing its due diligence investigations of C3;

c. the approval of C3 shareholders;

d. the completion, subject to shareholder approval, of the additional
placement of approximately $2m worth of C3 shares to clients of
Emerging Growth Capital and Poynton and Partners;

e. the appointment of Mr Harry Karelis as a director of C3 with
effect from the date of issue of the C3 shares to BTC;

f. the right of BTC to terminate in certain circumstances including
the S&P/ASX 200 Index falling by more than 15%.

B. The issue price for the placement will be the lower of 10.5 cents
or the volume weighted average price of C3 shares during the period
from the date that C3 and BTC execute a formal subscription agreement
to the date that shareholder approval is granted.

C. The number of options granted to BTC will be that amount which,
after allowing for the BTC funds invested in taking the placement and
the option exercise price of 29 cents, would on exercise take the
total of BTC funds invested in C3 to $4 million.

Grüsse

[Geldhahn]

Hallo,

CCE will ihre globale Strategie auf Ihrer Webseite auflisten:

CLINICAL CELL CULTURE LIMITED 2003-06-19 ASX-SIGNAL-G

HOMEX - Perth

+++++++++++++++++++++++++
19 June 2003, PERTH, AUSTRALIA: Clinical Cell Culture Ltd ASX=CCE
today announced the release of its strategic corporate overview
prepared by its management team in concert with its corporate
advisors, Poynton and Partners.

Since his commencement with Clinical Cell Culture Limited (C3)
earlier this year, Troels Jordansen, C3`s Chief Executive Officer,
has been focused on defining the company`s globalisation strategy.
This overview covers many of the strategic issues of interest brought
to Troels attention by the investment community.

Troels Jordansen said "C3 is currently moving towards the
implementation of its globalisation strategy. This document helps to
articulate the course that the management team and Board has set for
the Company."

The release of the corporate overview follows yesterday`s
announcement regarding the Heads of Agreement for an equity placement
of up to 19.99% in C3 by Biotech Capital Ltd (for further details on
the placement, please refer to the ASX announcement on C3`s website).
Biotech Capital Limited is managed by Challenger International Ltd
and is listed on the Australian Stock Exchange (Code: BTC, BTCO).

The overview will be posted on the C3`s website -
www.clinicalcellculture.com

ABOUT C3

Clinical Cell Culture is a publicly listed biomedical company, which
develops and distributes tissue-engineered cellular products for
autologous skin replacement.

The Company`s lead products and product candidates are CellSpray(R)
cultured epithelial autograft spray suspension for the treatment of
major burns, ReCell(R) autologous cell harvesting kit for the
treatment of small burns, pigment loss and scars and EpiGrow(R),
autologous epidermal derived fluid for the treatment of chronic
wounds. C3`s products have been used on more than 1,300 patients to
date.

Established in 1999, C3 was formed to commercialise products under
licence from the McComb Foundation to advance the research undertaken
by Fiona Wood and Marie Stoner into skin culture technologies. C3 is
based in Perth, Western Australia and provides a worldwide service
from its dedicated skin culture laboratory.

Grüsse

[Geldhahn]

Auch heute wieder ein Anstieg um 21% bei 4,4 Mio. gehandelten Aktien in Australien.

Grüsse

[IIBI]

Moin,

coole Sache, großes Volumen und Schluß fast auf TOP!!

Ich denke die 0,30 Aus$ werden wir bald wieder sehen,
leider geht in Deutschland nix um!!


Gruß

[IIBI]

@all

BTC hat knapp 20% der Firma gekauft, dann heute
ein Anstieg auf 0,235 AUS$, unter über 4 Mio Stück Umsatz!!!!!

Danach Trading Halt in Aussie-Land!!

Ankündigung bis spätestens nächsten Mittwoch!!

Kauft in Berlin so lange es noch geht!!!!!!!!!!!!!


Übernahme steht an, mind. 0,40 AUS$ meiner Meinung nach!!


Gruß

[Geldhahn]

Die heutige Verlautbarung und CCE fällt um 10% bei 4,3 mio. gehandelten Aktien:

CLINICAL CELL CULTURE LIMITED 2003-06-25 ASX-SIGNAL-G

HOMEX - Perth

+++++++++++++++++++++++++
EQUITY PLACEMENT INCREASED TO $7M (inclusive of BTC)

25th June 2003, PERTH, AUSTRALIA: Clinical Cell Culture Ltd (C3,
ASX:CCE) today announced that it has increased the current funding
round described in the C3s ASX announcement on 18 June 2003 from
approximately $5 million to approximately $7 million, which will
include a Share Purchase Plan Offer (SPP) of up to $1 million to
eligible shareholders.

C3`s Chairman, Mr Dalton Gooding, said that "after careful
consideration the Board unanimously agreed to increase the funding
round to $7 million to accommodate the substantial interest shown by
several institutions as well as allowing existing shareholders to
participate in this current round". Mr Gooding stated that he was
"very pleased to welcome several leading institutions including
Queensland Investment Corporation to the C3 share register alongside
BTC and C3`s current largest shareholder, Hunter Hall Investment
Management Limited. The balance of the funding round was placed with
predominantly sophisticated clients of Emerging Growth Capital and
Poynton and Partners.

C3 is also pleased to announce that, further to its announcement on
18 June 2003, BioTech Capital Limited (BTC) has completed its due
diligence and have executed a share subscription agreement. Due to
the increase in the amount of funds raised, the number of 31 December
2004, $0.29 call options being offered to BTC and other participating
shareholders has been decreased from approximately 1:7 to
approximately 2:19. The key conditions of the agreement with BTC are
set out in the attached Appendix.

The $1 million SPP will provide eligible shareholders with the
opportunity to subscribe for shares at the same price as that offered
to the institutional investors, being 10.5c. The record date for the
SPP has been set as at Friday 20 June 2003. Shareholders with a
registered address in either Australia or New Zealand will be
eligible to subscribe for ordinary shares under the SPP. The offer to
participate in the SPP will be mailed to eligible shareholders within
14 days. The SPP must comply with ASIC Class Order 02/831, which
limits the participation of each eligible shareholder to a maximum of
$5,000 worth of ordinary shares, and prevents C3 from offering the
$0.29 call options to eligible shareholders as part of the SPP.

Upon completion of the current funding round, C3`s cash reserves will
be in excess of $10 million. The proposed investment by BTC and other
investors, as well as the SPP will be subject to shareholder
approval, which is expected at the end of July.

For further information please contact:
Troels Jordansen
Clinical Cell Culture
Ph: [phone]
[e-mail]
or
eGCapital Poynton and Partners
Brad Ross-Sampson Brian Beresford
[phone] [phone]


APPENDIX

A. BTC has agreed to subscribe for approximately 29.5 million C3
shares (or approximately 19% - post the completion of the $7m
raising.)

B. The proposed investment by BTC is subject to:

a. the approval of C3 shareholders;

b. the completion, subject to shareholder approval, of the additional
placement of approximately $3m worth of C3 shares to professional and
sophisticated investor clients of eGCapital and Poynton and Partners.
This amount of approximately $3m does not include the proceeds from
any proposed share purchase plan offer made by C3 to existing
shareholders ;

c. the appointment of Mr Harry Karelis as a director of C3 with
effect from the date of issue of the C3 shares to BTC;

d. the right of BTC to terminate in certain circumstances including
the S&P/ASX 200 Index falling by more than 15% between 24 June 2003
and the date that shareholder approval is granted.

C. The issue price for the placement will be the lower of 10.5 cents
or the volume weighted average price of C3 shares during the period
from 24 June 2003 to the date that shareholder approval is granted.

D. The number of options granted to BTC will be that amount which,
after allowing for the BTC funds invested in taking the placement and
the option exercise price of 29 cents, would on exercise take the
total of BTC funds invested in C3 to $4 million.

Grüsse

[morchel]

Habe noch ein paar Stückchen aus Ecat´s Zeiten übrig: (0,25€)



morchel

[Sparda]

Ob sich nochmals ein Einstieg lohnt?

Habe noch aus Ecat-Zeiten einige rumliegen zu 0,29€.
Möglicherweise könnte man noch verbilligen.

Wer kann etwas dazu sagen.

Gruß
Sparda

[Geldhahn]

an Sparda

habe auch noch welche aus Ecat Zeiten, persönlich habe nicht die Absicht wieder zu kaufen bis wir das alte Niveau erreicht haben (0,22).

Grüsse

[morchel]

meine sind auch aus ECAT Zeiten. 0,25

http://stockhouse.ca/news/news.asp?newsid=1771278&tick=CCE

hab aber keine Ahnung über MK oder dergleichen!

Chart sieht gut aus...vieleicht ein wenig steil!

morchel

[morchel]

die ersten scheinen schon wieder in Germany einzusteigen!



morchel

[GlobInvest]

Hunter Hall Investment ist eingestiegen!

Ein gutes Zeichen!


http://www.hunterhall.com.au/

GlobInvest

[morchel]

soweit zu Hunter Hall

morchel

[Sparda]

Ich werde noch etwas abwarten und je nach Entwicklung noch mal nachlegen (vebilligen).
Verkaufen werde ich jedenfalls nicht.

cu
Sparda

[Geldhahn]

Heute wieder ein Anstieg um 8,5% auf AUS$ 0,19 bei 1,06 Mio. gehandelten Aktien.

Grüsse

[morchel]

wenn CCE heute nacht wieder zulegen kann könnte das ein Vorzeichen für einen bevorstehenden Ausbruch sein!

Kurs über 0,22 AUD wären schön!

morchel

[Geldhahn]

In der Zwischenzeit Seitwärtsbewegungen von 0,185 bis aktuell 0,195 bei nur 270.000 gehandelten Aktien.

Grüsse

[Geldhahn]

Heute wieder ein Anstieg von 0,18 auf 0,22 A$ (22%) bei 2,9 Mio. gehandelten Aktien. Es wurde bekanntgegeben, dass ein Vertrag mit Ventrex in USA für die Herstellung von ReCell abgeschlossen wurde. Man erwartet den Vertrieb für ReCell in Europa in 2004 zu haben.

Grüsse

[Geldhahn]

Heute wurden 14,2 Mio!! Aktien in Australien gehandelt. Der Kurs ist auf 0,235 gestiegen.
CCE hat auch den Vierteljahresbericht herausgegeben mit 0,976 Mio. Aus$ Cashburn bei 3 Mio. noch auf der Bank.
Es herrscht ein Optimismus, dass dieser Biotechwert durch die gesetzten Schritte auch die Produkte verkaufen wird können.

Grüsse

[Geldhahn]

Heute wieder ein Anstieg auf 0,245 bei 2,1 Mio. gehandelten Aktien.

Grüsse

[GlobInvest]

wenn sie ein neues 52 Wochen Hoch schaffen könnten wäre das sicher für den weiteren Auftrieb sehr dienlich!

Sehr gute und interessante Story! Bin investiert und werde es wohl noch weiter bleiben!

Möchte aber zu gleicher Zeit das Augenmerk auf einen anderen australischen Titel lenken der ebenfalls schon spektakuläre Erfolge erzielt hat!

PRR, in Germany nicht handelbar so weit ich weiß!
http://www.primabiomed.com.au

GlobInvest

[Geldhahn]

Heute ein Anstieg auf 0,27 bei 6 Mio gehandelten Aktien.

Grüsse

[Geldhahn]

0,36 in AUS (Euro 0,204)bei 14 Mio. Aktien. Eine US Patentanmeldung dürfte hier für den Anstieg verantwortlich sein.

Grüsse

[Sparda]

@all

warum wird dieser thread noch unter ecat geführt.
sollten wir nicht langsam umsteigen?
mir scheint, es gibt ja doch noch interessierte.

gruß
Sparda

[Geldhahn]

Heute wieder ein Rückgang auf 0,335 bei 8 Mio. Aktien.

@ Sparda: Du hast recht, W.O. scheint hier auf die australische Kennnummer zu greifen und bringt Ecat anstat CCE.
Ich werde diesen Thread nicht weiter führen, sondern einen anderen mit der richtigen Wertpapiernummer eröffnen.

Grüsse